[trbell]

1: Curr Opin Investig Drugs 2001 Oct;2(10):1441-3 Related Articles, Books Eziopitant. Pfizer.Evangelista S.Menarini Ricerche SpA, Sette Santi, Florence, Italy. sevangelista###menarini-ricerche.itPfizer is developing ezlopitant, a neurokinin-1 antagonist, for the potential treatment of irritable bowel syndrome (IBS). The compound had undergone phase II trials in the US and Europe, and phase I in Japan for treatment of chemotherapy-induced emesis [290988], [320737], [329187]. A phase II, double-blind, randomized study was performed to assess the safety and efficacy of ezlopitant for the control of cisplatin-induced emesis. Treatment was well tolerated [290988]. Although the compound effectively controls emesis, it is less effective in controlling nausea, and development has been discontinued for the emesis indication [347367]. Ezlopitant has undergone a pilot study in 14 IBS patients [367631].PMID: 11890362 [PubMed - in process] --------------------------------------------------------------------------------Curr Opin Investig Drugs 2001 Oct;2(10):1437-40 Related Articles, Books TAK-637. Takeda.Furness J B.Department of Anatomy and Cell Biology, University of Melbourne, Victoria, Australia. j.furness###unimelb.edu.auAbbott and Takeda are developing TAK-637, an orally active NK1 antagonist, for the potential treatment of urinary incontinence, depression, irritable bowel syndrome and pollakiuria. By November 1999, it was in phase II trials in Europe and phase I in Japan and the US for urinary incontinence [348496], [350686]. By October 2000, phase II trials had been initiated in the US for urinary incontinence, depression and IBS [381167], [386950], [419868], and in May 2001, these were scheduled to finish in 2002 [412024].PMID: 11890361 [PubMed - in process] --------------------------------------------------------------------------------